The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a stern warning regarding the circulation of counterfeit Noristerat Injection 200mg in Nigeria.
The agency reported that this fake contraceptive has been identified in Niger, Bauchi, and Kano States, particularly at the Coordinated Wholesale Centre in Kano.
In an official statement released recently, NAFDAC cautioned the public against the use of this counterfeit product, which has been found to be mislabeled and repackaged from Chlorpheniramine and Dexamethasone injection ampoules. The agency emphasized, “The counterfeit Noristerat Injection 200mg poses a significant health risk, as unsuspecting women might use a product that provides no contraceptive protection.”
NAFDAC confirmed that they have successfully tracked down and arrested the individual responsible for this counterfeit operation, assuring the public that efforts are ongoing to eliminate these dangerous products from the market. “We are dedicated to ensuring that only authentic and safe medical products reach the public,” NAFDAC stated.
To aid in consumer awareness, NAFDAC provided specific details about the counterfeit product, which bears the registration number 04-5715, a manufacturing date of September 2022, an expiry date of September 2027, and Lot Number KT02TTK.
It is important to note that genuine Noristerat 200mg is a contraceptive injection designed to provide eight weeks of pregnancy protection for short-term birth control. The counterfeit version, however, poses serious risks, including unintended pregnancies and potential health complications.
NAFDAC has called upon healthcare providers, pharmacists, and the public to remain vigilant and report any suspicious Noristerat Injection products. The agency emphasized the importance of community cooperation in safeguarding public health.
In reaffirming its commitment to protecting public health, NAFDAC announced that enhanced surveillance measures would be put in place to prevent similar incidents in the future. For more information, the agency encouraged the public to visit its official website or contact its offices nationwide.
